The short answer
Knownwell is our top pick for stacked chronic conditions. Score 7.5 of 10. Full primary-care telehealth model with obesity medicine integrated, board-certified physicians who coordinate across multiple chronic diseases and insurance billing as standard. The strongest pick if obesity is one of several conditions in your medical picture.
The short version
GLP-1 prescribing intersects with chronic-disease management in ways most telehealth programs aren't built for. A patient with type 2 diabetes plus chronic kidney disease plus moderate obesity needs a clinician who understands how semaglutide affects kidney function (favorably, per the FLOW trial), how it interacts with SGLT2 inhibitors (synergistic) and how to titrate alongside metformin. A patient with established cardiovascular disease needs the cardiovascular indication coded correctly for insurance. A patient with MASH (metabolic dysfunction-associated steatohepatitis) post the 2024 resmetirom approval needs coordination across hepatology and obesity medicine. Single-condition telehealth programs aren't structured for this. Primary-care telehealth programs are.
What we considered
- Primary-care or obesity-medicine board certification
- Coordinates GLP-1 with comorbidities (T2D, CKD, MASH, PCOS, CV disease)
- Codes prescriptions correctly for cardiovascular and renal indications
- Integrates with patient's existing endocrinologist, cardiologist, hepatologist where applicable
- Insurance billing for Medicare Part D and commercial PA on complex cases
Top pick: Knownwell
Knownwell's primary-care telehealth model integrates obesity medicine with the rest of the patient's medical picture, coordinates across cardiovascular, kidney and liver indications, and codes prescriptions correctly for Medicare Part D's CV-indication coverage of Wegovy.
Read the full Knownwell review →
Why Knownwell won this category
Knownwell's primary-care telehealth model is structured around treating the whole patient, not just the GLP-1 prescription. A typical Knownwell patient has obesity plus 2 to 3 other chronic conditions (most commonly hypertension, dyslipidemia, prediabetes or T2D, sleep apnea, depression, MASH). The visit notes integrate all of them rather than treating obesity in isolation, which produces better PA documentation and better long-term clinical management.
The cardiovascular coordination is the strongest in our chart. Patients with established CV disease (post-MI, post-stroke, symptomatic PAD) qualify for Medicare Part D coverage of Wegovy under the cardiovascular indication (NCD effective March 2024). Most general telehealth programs don't know the CV-indication coding. Knownwell does. They write the prescription for cardiovascular risk reduction, not for weight loss, and the Part D pharmacy fills it at the Medicare copay rather than denying it.
The kidney and liver coordination is the differentiator for CKD and MASH patients. The FLOW trial showed semaglutide reduces major kidney events in T2D patients with CKD by 24 percent. The ESSENCE trial showed semaglutide improves MASH histology. Programs that understand these indications can dose GLP-1s appropriately in CKD (no dose adjustment for semaglutide, dose adjustment for tirzepatide in severe CKD) and monitor liver enzymes in MASH. Knownwell's primary-care physicians follow the evidence in these subpopulations; most telehealth programs don't.
The trade-off is the onboarding timeline. Knownwell's intake takes 5 to 14 days because the workup includes labs, medical-records review and a full new-patient PCP visit. That's the right pace for patients with complex medical pictures, but the wrong pace for patients who just want a fast script. Cost is also higher: Knownwell bills insurance, and out-of-pocket varies by plan, but the cash-pay rate is among the higher in our chart.
Who this pick isn't for
Knownwell is not the right pick if obesity is your only relevant condition. The full primary-care workup is overkill for a patient without comorbidities looking for a straightforward GLP-1 prescription. For obesity-only patients, Form Health (obesity-medicine specialist) or PlushCare (general PCP) deliver the prescription with less diagnostic overhead.
Knownwell is also not the right pick if you specifically want cash-pay compounded medication. Knownwell prescribes brand Wegovy or Zepbound through insurance billing; they don't have a compounded option as the primary path. For patients without insurance coverage or who specifically want the compounded cost savings, Mochi or Henry are the relevant alternatives.
And Knownwell doesn't fit if you already have a strong PCP relationship and just want a GLP-1 prescription added without duplicating primary care. In that case, ask your existing PCP first (free if you have insurance, faster than any telehealth path). If your PCP refuses to prescribe GLP-1 weight loss, then Form Health (single-condition obesity-medicine specialist) is the cleanest add-on that doesn't try to replace your PCP.
Runner-up: Form Health
Form Health is the runner-up specifically for patients whose primary condition is obesity with one or two comorbidities; the board-certified obesity medicine focus is sharper, the primary-care integration is less complete.
Read the full Form Health review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| Knownwell | 7.5 | Insurance-billed | Month-to-month | 14 days |
| Form Health | 7.6 | $299/mo | Month-to-month | 7 days |
| 9amHealth | 7.4 | $25/mo | Month-to-month | 5 days |
Other strong picks
Frequently asked
Can I take a GLP-1 with chronic kidney disease?
Yes, usually. Semaglutide has no dose adjustment recommendation for any stage of CKD per the prescribing information, and the FLOW trial published in NEJM 2024 showed semaglutide reduces major kidney events by 24 percent in T2D patients with CKD. Tirzepatide has limited data in severe CKD (eGFR under 30) and use is generally avoided in those patients. A clinician who understands CKD subgroups is important.
What about MASH (fatty liver disease)?
Semaglutide showed significant improvement in MASH histology in the ESSENCE trial (NEJM 2024). Tirzepatide showed similar effects in the SYNERGY-NASH trial. Both drugs are reasonable choices in patients with MASH plus obesity. Coordinating with hepatology, monitoring liver enzymes and adjusting other hepatotoxic medications matters. The FDA approved resmetirom (Rezdiffra) for MASH in March 2024, which is sometimes combined with GLP-1; that combination needs hepatology coordination.
What if I have established cardiovascular disease?
Semaglutide is the strongest pick. The SELECT trial showed semaglutide 2.4 mg reduces major adverse cardiovascular events by 20 percent in patients with established CV disease and overweight/obesity. The FDA approved the CV indication in March 2024. Medicare Part D covers Wegovy specifically for the CV indication (not for weight loss alone). Coding the prescription correctly is the key; a clinician who routinely handles CV-indication coding is the right pick.
Can I take a GLP-1 with SGLT2 inhibitors or metformin?
Yes, with monitoring. Combining a GLP-1 with metformin is standard and well-tolerated. Combining a GLP-1 with an SGLT2 inhibitor (empagliflozin, dapagliflozin) is increasingly common in T2D with renal or cardiovascular indication; the combination provides additive benefits on weight, glycemic control, kidney and cardiovascular outcomes. Watch for volume depletion if both are added quickly.
What about PCOS?
PCOS is one of the strongest off-label indications for GLP-1. Published evidence shows improvements in insulin sensitivity, menstrual regularity, androgen levels and weight beyond what calorie deficit alone produces. Most insurance doesn't approve GLP-1 specifically for PCOS, so patients usually need obesity criteria (BMI 30 plus or BMI 27 plus comorbidity) for insurance coverage. PCOS counts as a comorbidity for the BMI 27 plus pathway. Our PCOS best-of covers this in detail.
What's the safest GLP-1 in pregnancy?
None of them. Semaglutide and tirzepatide are both Pregnancy Category C with no human data; animal studies show developmental effects. Standard recommendation is to discontinue GLP-1 at least 2 months before planned pregnancy (semaglutide half-life is 7 days, so 5 half-lives is around 5 weeks, with extra margin). A clinician who follows obesity-medicine guidelines on contraception and pregnancy planning matters for women of reproductive age.
Do I need to see specialists in addition to my telehealth program?
Often yes. Patients with stacked chronic conditions typically benefit from continuity with an endocrinologist (for T2D, thyroid, complex hormonal), cardiologist (for established CV disease) or hepatologist (for MASH). The telehealth program manages the GLP-1 component and coordinates with the specialists. Programs like Knownwell make this coordination explicit; single-condition programs leave it to the patient to bridge.
Sources
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with T2D. NEJM 2024 (FLOW trial)
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. NEJM 2023 (SELECT trial)
- Newsome PN, et al. Semaglutide in patients with MASH. NEJM 2024 (ESSENCE trial)
- CMS: National Coverage Determination on Wegovy for cardiovascular risk reduction (March 2024)
- American Diabetes Association: 2026 Standards of Care, pharmacologic approaches in obesity and T2D
Related
